Critical appraisal of efficacy and safety of abatacept in the treatment of refractory rheumatoid arthritis

about

Critical appraisal of efficacy and safety of abatacept in the treatment of refractory rheumatoid arthritis

Item

http://www.wikidata.org/entity/Q37301126

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 02 February 2012

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Critical appraisal of efficacy ...... efractory rheumatoid arthritis

@en

Critical appraisal of efficacy ...... fractory rheumatoid arthritis.

@nl

type

Item

label

Critical appraisal of efficacy ...... efractory rheumatoid arthritis

@en

Critical appraisal of efficacy ...... fractory rheumatoid arthritis.

@nl

prefLabel

Critical appraisal of efficacy ...... efractory rheumatoid arthritis

@en

Critical appraisal of efficacy ...... fractory rheumatoid arthritis.

@nl

P1476

Critical appraisal of efficacy ...... efractory rheumatoid arthritis

@en

P2093

Jill M Augustine

http://www.w3.org/2001/XMLSchema#string

Lisa M Lundquist

http://www.w3.org/2001/XMLSchema#string

Sabrina W Cole

http://www.w3.org/2001/XMLSchema#string

P2860

The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis

Cytokine pathways and joint inflammation in rheumatoid arthritis.

Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial.

Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial.

American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.

American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials.

Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate.

Abatacept improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate treatment

New therapies for treatment of rheumatoid arthritis.

Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate.

P304

9-19

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/OARRR.S16073

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-02-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27790008

http://www.w3.org/2001/XMLSchema#string

P932

5045095

http://www.w3.org/2001/XMLSchema#string